sinocelltech sinobiological
biotech company with 18 years technological accumulation. mature technology platform for monoclonal antibody,recombinant protein,vaccine etc. own significant cost competitiveness advantage
Frank Lai
BD directorsinopharm
www.sinopharm.com
our business covers R&D,manufacturing, logistics and distribution of medicinal products.
our business covers R&D,manufacturing, logistics and distribution of medicinal products.
shuyuan PAN
associate director(R&D managing department)Sinovant
Sinovant Sciences (http://www.sinovant.com) is an innovative biopharmaceutical company based in Shanghai, Beijing and Hong Kong. Sinovant was founded by Chinese scientists and physicians, including Chinese “Returnees”. Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.
Sinovant has a diverse pipeline of 11 investigational products in development, among which 5 drug candidates are in phase III or beyond. Our products span over 6 therapeutic areas including oncology, infectious disease, urology / nephrology, gastrointestinal diseases, dermatology and rare diseases.
Henry Xiong
Senior BD DirectorSirtex Medical
Global medical device company focused on oncology and interventional therapy.
Michelle You
BD managerSixty Degree Capital
Sixty Degree Capital Inc. is a Toronto based venture capital investor with US$200MM+ under management investing across North America and Asia. We are dedicated to building strong, long-term relationships with our partners and investors within our industries of focus. Our Toronto office has been actively investing in Healthcare related sectors in the past several years. By partnering with top tier lead investors such as Lumira Ventures, Versant Ventures, Google Ventures, iNovia Capital etc., we have deployed our capital into some exciting North American companies including Schrödinger (Drug discovery platform), Turnstone Biologics and Northern Biologics (Immuno Oncology therapeutics), as well as Antios Therapeutics (HBV innovative therapy). As a growth to late stage investor, our initial cheque size ranges from USD 3 to 5m with reserve of USD 10~20m.